

## TABLE OF CONTENTS

### References

**Docket No.:** 1980N-0208

**Title:** **Biological Products; Bacterial Vaccines and Toxoids; Implementation of Efficacy Review (Non-AVA); Final Rule and Final Order**

Tab #	Reference Title
1	“Table of Reportable Events Following Vaccination,” <a href="http://www.vaers.hhs.gov/reportable.htm">http://www.vaers.hhs.gov/reportable.htm</a> . (FDA has verified the Web site address, but we note subsequent changes to the Web site might occur after this document publishes in the FEDERAL REGISTER).
2	“Guidance for Industry: How to Complete the Vaccine Adverse Event Reporting System Form (VAERS-1)”, September 1998, <a href="http://www.fda.gov/cber/gdlns/vaers-1.pdf">http://www.fda.gov/cber/gdlns/vaers-1.pdf</a> . (FDA has verified the Web site address, but we note subsequent changes to the Web site might occur after this document publishes in the FEDERAL REGISTER).
3	“Estimated Vaccination Coverage With 3+DTP Among Children 19-35 Months of Age by Race/Ethnicity, and by State and Immunization Action Plan Area—U.S., National Immunization Survey, Q3/2000 – Q2/2001”, <a href="http://www.cdc.gov/nip/coverage/NIS/00-01/tab19-3dpt_race_iap.htm">http://www.cdc.gov/nip/coverage/NIS/00-01/tab19-3dpt_race_iap.htm</a> . (FDA has verified the Web site address, but we note subsequent changes to the Web site might occur after this document publishes in the FEDERAL REGISTER).
4	Protecting Our Kids: What Is Causing the Current Shortage in Childhood Vaccines?—Testimony Before the Committee on Governmental Affairs, United States Senate, June 12, 2002, <a href="http://www.cdc.gov/nip/news/testimonies/vac-shortages-walt-6-12-2002.htm">http://www.cdc.gov/nip/news/testimonies/vac-shortages-walt-6-12-2002.htm</a> . (FDA has verified the Web site address, but we note subsequent changes to the Web site might occur after this document publishes in the FEDERAL REGISTER).
5	August 1, 1996 (61 FR 40153); Revocation of Certain Regulations; Biological Products; Final Rule.
6	Colditz, et al., “Efficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta Analysis of the Published Literature”, <i>Journal of the American Medical Association</i> , 271:698-702, 1994.
7	FDA/CBER VRBPAC Meeting Transcript (February 17, 2005), <a href="http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4087T2.htm">http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4087T2.htm</a>
8	FDA/CBER VRBPAC Meeting Transcript (May 6, 2004), <a href="http://www.fda.gov/ohrms/dockets/ac/04/transcripts/4038t1.htm">http://www.fda.gov/ohrms/dockets/ac/04/transcripts/4038t1.htm</a>
9	FDA/CBER VRBPAC Meeting Transcript (May 8, 2003), <a href="http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3948t1.txt">http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3948t1.txt</a>
10	Guidance for FDA Staff: The Leveraging Handbook; June 2003, <a href="http://www.fda.gov/cber/gdlns/leverhnbk.pdf">http://www.fda.gov/cber/gdlns/leverhnbk.pdf</a>